On 05 August 2016
Cadila Healthcare announced the acquisition of two ANDAs by its 100% subsidiary, Zydus Worldwide DMCC from Teva that were being divested by Teva as a pre-condition to its acquisition of Allergan's generic business. The acquisition of these ANDAs was contingent on the closing of the Teva-Allergan Generics transaction and approval by the US Federal Trade Commission.Powered by Capital Market - Live News
